Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Vactosertib
Cat. No.:
OB0225LY-0190
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR and HPLC.
Size:
Add to basket
Product Overview
Description:
Vactosertib is an anti-TGF-β drug designed to modulate cellular responses to the microenvironment.
Synonym:
TEW-7197; EW-7197; 1352608-82-2; 2-Fluoro-N-[[5-(6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-imidazol-2-yl]methyl]aniline; N-((4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline; N-[[4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-H-imidazol-2-yl]methyl]-2-fluoroaniline
CAS No.:
1352608-82-2
Compound CID:
54766013
Formula:
C22H18FN7
Formula Weight:
399.42
Specification
Relative Density:
1.40 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Vactosertib can be used to study fibrosis models or play an important role in tumor microenvironment studies.
Library Information
Targets:
ALK family
Receptors:
ALK1; ALK2; ALK3; ALK4; ALK5
Pathways:
Stem cells; Angiogenesis; Tyrosine kinase/adaptors; TGF-β/Smad signaling
Plate Number:
AOCL-3
Plate Location:
d4
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
60 mg/mL; 150.22 mM
Water Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
Ethanol Max Solubility:
40 mg/mL; 100.1 mM
ALogP:
3.621
HBA_Count:
4
HBD_Count:
2
Rotatable Bond:
5
